NAIMIT
Novel immunotherapies for type 1 diabetes
| Coordinatore | KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
| Nazionalità Coordinatore | Belgium [BE] |
| Sito del progetto | http://www.naimit.eu |
| Totale costo | 14˙247˙400 € |
| EC contributo | 10˙920˙800 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2009-single-stage |
| Funding Scheme | CP-IP |
| Anno di inizio | 2009 |
| Periodo (anno-mese-giorno) | 2009-11-01 - 2015-04-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | coordinator | 1˙636˙200.80 |
| 2 |
ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
NL (LEIDEN) | participant | 1˙074˙962.40 |
| 3 |
MEDIZINISCHE HOCHSCHULE HANNOVER
Organization address
address: Carl-Neuberg-Strasse 1 contact info |
DE (HANNOVER) | participant | 928˙500.00 |
| 4 |
Immunocore Limited
Organization address
address: Milton Park 57c contact info |
UK (Abingdon) | participant | 832˙500.00 |
| 5 |
KING'S COLLEGE LONDON
Organization address
address: Strand contact info |
UK (LONDON) | participant | 805˙299.60 |
| 6 |
UNIVERSITY OF BRISTOL
Organization address
address: TYNDALL AVENUE SENATE HOUSE contact info |
UK (BRISTOL) | participant | 709˙845.60 |
| 7 |
UNIVERSITE LIBRE DE BRUXELLES
Organization address
address: Avenue Franklin Roosevelt 50 contact info |
BE (BRUXELLES) | participant | 699˙300.00 |
| 8 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
UK (CAMBRIDGE) | participant | 670˙500.00 |
| 9 |
ActoGeniX NV
Organization address
address: Technologiepark 4 contact info |
BE (Zwijnaarde) | participant | 652˙500.00 |
| 10 |
JOHANN WOLFGANG GOETHE UNIVERSITAET FRANKFURT AM MAIN
Organization address
address: GRUNEBURGPLATZ 1 contact info |
DE (FRANKFURT AM MAIN) | participant | 650˙100.00 |
| 11 |
FUNDACAO CALOUSTE GULBENKIAN
Organization address
address: AVENIDA DE BERNA 45A contact info |
PT (LISBOA) | participant | 597˙300.00 |
| 12 |
UNIVERSITA' DEGLI STUDI DI SIENA
Organization address
address: VIA BANCHI DI SOTTO 55 contact info |
IT (SIENA) | participant | 596˙100.00 |
| 13 |
CARDIFF UNIVERSITY
Organization address
address: Newport Road 30-36 contact info |
UK (CARDIFF) | participant | 511˙154.40 |
| 14 |
UNIVERSITA DI PISA
Organization address
address: Lungarno Pacinotti 43/44 contact info |
IT (PISA) | participant | 494˙100.00 |
| 15 |
DanDrit Biotech A/S
Organization address
address: Fruebjergvej 3 contact info |
DK (Copenhagen) | participant | 62˙437.20 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'This proposal will pioneer the concept of tailored interventions with minimal immune system interference in new onset T1DM, leading to beta-cell protection and restoration, based on a solid understanding of the disease pathogenesis. This will enable experimental findings to be adopted for future clinical application. Four work packages are grouped around ‘Reversal of autoimmunity’, in which two key players of the immune system in beta-cell destruction will be targeted: the dendritic cell (WP1: Re-educating antigen-presenting cells) and the T-lymphocyte (WP2: Restoring the T-cell balance). In both cell types, interventions using steroid hormones (vitamin D and glucocorticoids) will be used to induce tolerance. Moreover, novel interventions using soluble T-cell receptors to target immune cells and beta-cells in an antigen-specific way (WP3: TCR-mediated immunotherapy) will be introduced. Novel mucosal interventions using probiotics and recombinant L. lactis as a carrier for specific peptides in combination with cytokines (WP4: Mucosal intervention for tolerance restoration) will be studied for their immune modulating potential. A full work package (WP5: Beta-cell protection and restoration – the dialogue with the immune system) is dedicated to the beta-cell and its role in driving and amplifying the immune attack through communication between beta-cells and the immune system. The last scientific work package (WP6: Pharmacogenetics) will identify genetic profiles within patients that predict responsiveness to the steroid interventions proposed. WP7 and 8 are dedicated to training and management of the consortium. For this purpose, a multidisciplinary consortium of leading European diabetologists and immunologists from 11 academic research institutions, in co-operation with 3 SMEs developing novel technologies allowing translation of basic research results towards clinical applications, has been established.'
Introduzione (Teaser)
Type 1 diabetes (T1D) is an autoimmune disease, in which the insulin-producing beta cells are destroyed by infiltrating immune cells. Recent evidence has made it clear that the beta cells, next to the destructive role of the immune system, are also playing an active role in their own destruction.
Altri progetti dello stesso programma (FP7-HEALTH)
BIO-NMD (2009)
Identifying and validating pre-clinical biomarkers for diagnostics and therapeutics of Neuromuscular Disorders
Read MoreOPTIBIRTH (2012)
"Improving the organisation of maternal health service delivery, and optimising childbirth, by increasing vaginal birth after caesarean section (VBAC) through enhanced women-centred care"
Read More